发明名称 RNAi probes targeting cancer-related proteins
摘要 RNAi sequences that are useful as therapeutics in the treatment of cancers of various types, including prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma and melanoma; and Alzheimer's disease. These sequences target clusterin, IGFBP-5, IGFBP-2, both IGFBP-2 and -5 simultaneously, Mitf, and B-raf. The invention further provides for the use of these RNAi sequences in the treatment of cancers of various types, including prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma and melanoma; and Alzheimer's disease, and a method of treating such conditions through the administration of the RNA molecules with RNAi activity to an individual, including a human individual in need of such treatment.
申请公布号 US8759308(B2) 申请公布日期 2014.06.24
申请号 US201012845521 申请日期 2010.07.28
申请人 The University of British Columbia 发明人 Gleave Martin;Jansen Burkhard;Trougakos Ioannis P;Gonos Efstathios;Signaevsky Maxim;Beraldi Eliana
分类号 A61K48/00 主分类号 A61K48/00
代理机构 Larson & Anderson, LLC 代理人 Larson & Anderson, LLC
主权项 1. A method of treating a cancer that expresses clusterin, comprising administering to an individual in need of treatment an RNA molecule having a sequence effective to mediate degradation or block translation of mRNA that is the transcriptional product of a target gene, wherein the target gene encodes clusterin, and the RNA molecule comprises a sequence of bases as defined by Seq. ID No. 6, wherein the individual has a cancer that expresses clusterin.
地址 Vancouver CA